8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____________________

FORM 8-K

____________________

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (date of earliest event reported): November 21, 2012

K-V PHARMACEUTICAL COMPANY

(Exact name of registrant as specified in its charter)

____________________

Delaware	1-9601	43-0618919
(State or other jurisdiction	(Commission	(I.R.S. Employer
of incorporation)	File Number)	Identification No.)

2280 Schuetz Road
St. Louis, MO	63146
(Address of principal executive offices)	(Zip Code)

(314) 645-6600

(Registrant's telephone number, including area code)

____________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□  Written communications pursuant to Rule 425 under the Securities Act.

□  Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

□  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

□  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

Item 7.01 Regulation FD Disclosure.

As previously disclosed in its Current Report on Form 8-K filed August 4, 2012, K-V Pharmaceutical Company (the “Company”) and certain of its wholly-owned domestic subsidiaries (collectively, the “Debtors”) filed voluntary petitions for reorganization under Chapter 11 of the United States Bankruptcy Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the Southern District of New York (the “Bankruptcy Court”).

October Monthly Operating Report

On November 15, 2012, the Debtors filed with the Bankruptcy Court their Monthly Operating Report for the period from October 1, 2012 to October 31, 2012 (the “MOR-October 2012”), which included certain performance metrics for the Company’s Makena®  product. A copy of the MOR-October 2012 is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Authorization to Use Cash Collateral

As previously reported in the Company’s Current Report on Form 8-K filed August 13, 2012, the Bankruptcy Court entered an Agreed Interim Order on August 10, 2012, which, among other things, authorized the Debtors’ use of their cash collateral.

On September 14, 2012, the Bankruptcy Court entered an Order (the “Final Cash Collateral Order”), which, among other things, authorized the Debtors to use their cash collateral through and including October 18, 2012.

On October 16, 2012, the Bankruptcy Court “So Ordered” a stipulation extending the Debtors’ authorization to use their cash collateral through and including November 21, 2012, unless such authority is terminated in accordance with the terms and conditions set forth in the Final Cash Collateral Order.

On November 21, 2012, the Bankruptcy Court entered a stipulation and order further extending the Debtors’ authorization to use their cash collateral through and including January 9, 2013, unless such authority is terminated in accordance with the terms and conditions set forth in the Final Cash Collateral Order.

Motion Filed by Subordinated Notes Trustee

On November 21, 2012, Deutsche Bank Trust Company Americas (the “Trustee”), as Trustee of the $200 million aggregate principal amount of convertible subordinated notes issued by the Company (the “Subordinated Notes”), filed a motion with the Bankruptcy Court for entry of an order, pursuant to Rule 2004 of the Federal Rules of Bankruptcy Procedure, directing the examination of the Company and certain other parties.  Based upon the information available to it, the Trustee alleges that the Indenture governing the Subordinated Notes, which was filed by the Company on Form 8-K on May 21, 2003, may not be the actual indenture under which the Subordinated Notes were issued.  In particular, the Trustee alleges that, in relevant part, the Indenture should require that indebtedness which ranks senior to the Subordinated Notes receive “payment in full” before any distribution to holders of the Subordinated Notes, rather than “payment in full in cash or cash equivalent” which is provided for in the Indenture filed by the Company on Form 8-K.  This provision could have implications relative to the application of the subordination provisions of the Indenture with respect to the relative rights of holders of senior debt and the Subordinated Notes. The Company believes that the Indenture filed on Form 8-K is the correct version, however there can be no assurance that the Company will prevail in its assertion.

Regulation FD Disclosure

This Current Report on Form 8-K (including Exhibit 99.1 hereto and any information contained therein) shall not be deemed to be an admission as to the materiality of any information required to be disclosed solely by reason of Regulation FD. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

 Cautionary Statement Regarding Financial and Operating Data

The Company cautions investors and potential investors not to place undue reliance upon the information contained in the MOR-October 2012, which was not prepared for the purpose of providing the basis for an investment decision relating to any of the securities of the Company. The Company cannot predict what the ultimate value of any of its securities may be and it remains too early to determine whether holders of any such securities will receive any distribution in the Debtors’ reorganization. In particular, in most cases under Chapter 11 of the Bankruptcy Code, holders of equity securities receive little or no recovery of value from their investment. The MOR-October 2012 is limited in scope, covers a limited time period and has been prepared solely for the purpose of complying with the monthly reporting requirements of the Office of the United States Trustee of the Southern District of New York and the Bankruptcy Court. The MOR-October 2012 was not audited or reviewed by independent accountants, is in a format prescribed by applicable bankruptcy laws and regulations and is subject to future adjustment and reconciliation. The MOR-October 2012 does not include all of the information and footnotes required by GAAP. Therefore, the MOR-October 2012 does not necessarily contain all information required in filings pursuant to the Exchange Act, or may present such information differently from such requirements. There can be no assurance that, from the perspective of an investor or potential investor in the Company’s securities, the MOR-October 2012 is complete. The MOR-October 2012 also contains information for periods which are shorter or otherwise different from those required in the Company’s reports pursuant to the Exchange Act, and such information might not be indicative of the Company’s financial condition or operating results for the period that would be reflected in the Company’s financial statements or in its reports pursuant to the Exchange Act. Results set forth in the MOR-October 2012 should not be viewed as indicative of future results.

Item 9.01              Financial Statements and Exhibits.

(d)           The following exhibits are furnished as part of this report:

Exhibit Number                            Description

99.1                                         Monthly Operating Report for thePeriod from October 1, 2012 toOctober 31, 2012

The Company will post this Form 8-K on its Internet website at www.kvpharmaceutical.com.  References to the Company’s website address are included in this Form 8-K only as inactive textual references and the Company does not intend them to be active links to the website.  Information contained on the website does not constitute part of this Form 8-K.

*            *          *

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated:  November 27, 2012

K-V PHARMACEUTICAL COMPANY
By:	/s/ Patrick J. Christmas
	Patrick J. Christmas
	Vice President, General Counsel and
	Secretary

EX-99.1

Exhibit 99.1

United States Bankruptcy Court
Southern District of New York
	X
In re:	:	Chapter 11
	:
K-V Discovery Solutions, Inc. et al.:	:	Case No.  12-13346 (ALG)
	:
Debtors.	X	Jointly Administered

Monthly Operating Report for the Period

October 1, 2012 to October 31, 2012

Debtors' Address:	2280 Schuetz Road
	St. Louis, Missouri 63146
	Telephone:  (314) 645-6600
Debtors' Attorneys:	Willkie Farr & Gallagher LLP
	787 Seventh Avenue
	New York, New York 10019
	Telephone:  (212) 728-8000

This Monthly Operating Report ("MOR") has been prepared solely for the purposes of complying with the monthly reporting requirements applicable in these Chapter 11 cases and is in a format that the Debtors believe is acceptable to the United States Trustee.  The financial information contained herein is limited in scope and covers a limited time period. Moreover, such information is preliminary and unaudited, and is not prepared in accordance with accounting principles generally accepted in the United States ("GAAP").

I declare under penalty of perjury that this report and the attached documents are true and correct to the best of my knowledge and belief.

/s/ Thomas S. McHugh	November 15, 2012
Thomas S. McHugh
Chief Financial Officer
K-V Pharmaceutical Company

In re	K-V DISCOVERY SOLUTIONS, INC., et al.	Case No.	12-13346
	Debtors.	Reporting Period:	10/1/12 -10/31/12
		Federal Tax I.D.#	13-1587982

CORPORATE MONTHLY OPERATING REPORT

File with the Court and submit a copy to the United States Trustee within 20 days after the end of the month and submit a copy of the report to any official committee appointed in the case.

(Reports for Rochester and Buffalo Divisions of Western District of New York are due 15 days after the end of the month, as are the reports for Southern District of New York.)

REQUIRED DOCUMENTS	Form No.	Document Attached	Explanation Attached
Schedule of Cash Receipts and Disbursements	MOR-1	x
Bank Reconciliation (or copies of debtor's bank reconciliations)	MOR-1	x
Copies of bank statements			x
Cash disbursements journals			x
Statement of Operations	MOR-2	x
Balance Sheet	MOR-3	x
Status of Post-petition Taxes	MOR-4	x	x
Copies of IRS Form 6123 or payment receipt (See Notes to MOR 4)			x
Copies of tax returns filed during reporting period (See Notes to MOR 4)			x
Summary of Unpaid Post-petition Debts (See Notes to MOR 4)	MOR-4		x
Listing of Aged Accounts Payable (See MOR 7)		x
Accounts Receivable Reconciliation and Aging	MOR-5	x
Taxes Reconciliation and Aging (See MOR 7)	MOR-5		x
Payments to Insiders and Professionals	MOR-6	x
Post Petition Status of Secured Notes, Leases Payable	MOR-6	x
Debtor Questionnaire	MOR-7	x
Makena® Performance Metrics		x

- 2 -

NOTES TO MONTHLY OPERATING REPORT

This MOR includes activity from the following Debtors:

Debtor	Case Number
K-V Discovery Solutions, Inc.	12-13346
K-V Pharmaceutical Company	12-13347
Ther-Rx Corporation	12-13348
K-V Generic Pharmaceuticals, Inc.	12-13349
Zeratech Technologies USA, Inc.	12-13350
Drug Tech Corporation	12-13351
K-V Solutions USA, Inc.	12-13352
FP1096, Inc.	12-13353

General Notes:

The financial statements and supplemental information contained herein are preliminary, unaudited, and may not comply in all material respects with GAAP.  In addition, the financial statements and supplemental information contained herein represent consolidated information.

The unaudited consolidated financial statements have been derived from the books and records of the Debtors and exclude activity for their non-debtor subsidiaries. This information has not been subject to certain procedures that would typically be applied to financial information in accordance with GAAP, and upon application of such procedures the financial information could be subject to changes, and these changes could be material.

The financial information contained herein is presented on a preliminary and unaudited basis and remains subject to future adjustment.  The Debtors are reviewing their books and records and other information on an ongoing basis to determine whether the financial statements should be supplemented or otherwise amended.  The Debtors reserve the right to file, at any time, such supplements or amendments to the financial statements that form a part of this MOR.  The financial statements should not be considered an admission regarding any of the Debtors’ income, expenditures or general financial condition, but rather, a current compilation of the Debtors’ books and records.  The Debtors do not make, and specifically disclaim, any representation or warranty as to the completeness or accuracy of the information set forth herein.

The unaudited consolidated financial statements contained herein have been prepared on a going concern basis and do not reflect or provide all of the possible consequences of the ongoing chapter 11 cases.  Specifically, the unaudited consolidated financial statements do not present the amount which will ultimately be paid to settle liabilities and contingencies which may be required in these cases.  As a result of the chapter 11 proceedings, the Debtors may take, or may be required to take, actions which may cause assets to be realized, or liabilities to be liquidated, for amounts other than those reflected in the unaudited consolidated financial statements.

Certain footnote disclosures normally included in unaudited consolidated financial statements prepared in accordance with GAAP have been condensed or omitted.  Preparation of the financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of expenses during the reporting period.  The results of operations contained herein are not necessarily indicative of results which may be expected for any other period or for the full year and may not necessarily reflect the consolidated results of operations and financial position of the Debtors in the future.

- 3 -

MOR-1:

SCHEDULE OF CASH RECEIPTS AND DISBURSEMENTS 1

(Dollars in thousands)

Debtor	Case Number	Cash Receipts
Ther-Rx Corporation	12-13348	$	7,226
K-V Pharmaceutical Company	12-13347		87
DrugTech Corporation	12-13351		0
K-V Discovery Solutions, Inc.	12-13346		0
K-V Generic Pharmaceuticals, Inc.	12-13349		0
Zeratech Technologies USA, Inc.	12-13350		0
K-V Solutions USA Inc.	12-13352		0
FP1096, Inc.	12-13353		0
Total Cash Receipts		$	7,313
Debtor	Case Number	Cash 2 Disbursements
K-V Pharmaceutical Company	12-13347	$	(6,191	)
Ther-Rx Corporation	12-13348		(2,334	)
DrugTech Corporation	12-13351		(8	)
K-V Discovery Solutions, Inc.	12-13346		0
K-V Generic Pharmaceuticals, Inc.	12-13349		0
Zeratech Technologies USA, Inc.	12-13350		0
K-V Solutions USA Inc.	12-13352		0
FP1096, Inc.	12-13353		0
Total Cash Disbursements		$	(8,533	)

Notes

1 – Cash is received and disbursed by the Debtors as described in the Debtors’ motion to approve continued use of their cash management system (which motion was granted on an interim basis pursuant to an order entered by the Bankruptcy Court on August 7, 2012 and on a second interim basis pursuant to an order entered by the Bankruptcy Court on September 28, 2012) and is consistent with the Debtors’ historical cash management practices.  All amounts listed are the balances reported by the bank as of the end of the reporting period.  Copies of bank statements will be provided upon reasonable request in writing to counsel for the Debtors.

2 – Cash disbursements during the month of October 2012 include $467 of outstanding checks.

- 4 -

MOR-1 (CON’T):

BANK RECONCILIATIONS 1, 2, 3, 4, 5, 6

(Dollars in thousands)

Debtor	Case Number	Bank and Account Description	Bank Account No. Ending In		Bank Balance
K-V Pharmaceutical Company	12-13347	Fifth Third Money Market / Investment Account	1225		$	21,687
K-V Pharmaceutical Company	12-13347	Fifth Third Bank / Nesher Escrow Account	0383			7,513
K-V Pharmaceutical Company	12-13347	Fifth Third Bank / Operating Account	9158			7,224
K-V Pharmaceutical Company	12-13347	Fifth Third Bank / PDI Escrow Account	1876	5		1,819
K-V Pharmaceutical Company	12-13347	Commerce Bank / Deposit Account	2433			150
K-V Pharmaceutical Company	12-13347	AMEX Centurion Bank / Certificate of Deposit	8420			75
K-V Pharmaceutical Company	12-13347	Fifth Third Bank / Utility Deposit	0479	7		2
Drug Tech Corporation	12-13351	US Bank / DrugTech Custody Account	3256			4
Drug Tech Corporation	12-13351	Wells Fargo Bank/ DrugTech Operating Acct	6823			1
					$	38,475

Notes

1 – The Debtors have not included copies of their bank statements or cash disbursement journals due to the voluminous nature of these reports.  Copies of the Debtors’ bank statements and cash disbursement journals will be provided upon reasonable request in writing to counsel for the Debtors.

2 – The Debtors reconcile their bank accounts on a monthly basis.

3 – The Debtors have excluded accounts with no balance as of the end of the reporting period.

4 – The Debtors’ bank balances exclude $503 of outstanding checks.

5 – This account was inadvertently identified in the Debtors’ motion to approve continued use of their cash management system as ending in 4187.

6 – During this reporting period, the Debtors closed a bank account in the name of K-V Pharmaceutical Company with Bank of America (“Payroll Account”, bank account no. ending in 6170).

7 – The Debtors opened this bank account post-petition on August 28, 2012 in accordance with the order of the Bankruptcy Court, entered on August 23, 2012, that, among other things, established procedures for providing deposits to the Debtors’ utility service providers that request adequate assurance of payment and deemed such utility service providers to have adequate assurance of payment.

- 5 -

MOR-2:

CONSOLIDATED STATEMENT OF OPERATIONS

(Unaudited; Dollars in thousands)

	For the  Month Ended  October 31, 20121
Net revenues	$	7,730
Cost of sales		139
Gross profit		7,591
Research and development		382
Selling and administrative		6,585
Operating expenses		6,967
Operating income		624
Interest, net and other		0
Reorganization items, net		1,507
Total other expense, net		1,507
Loss from continuing operations before income taxes		(883	)
Income tax provision		1,008
Net loss from continuing operations	$	(1,891	)

Notes

1 – The Debtors prepare their income statement on an accrual basis.  Accordingly, the Debtors’ Statement of Operations, as set forth in this MOR, reflects the results of the Debtors’ operations for the month of October 2012.

- 6 -

MOR-3:

CONSOLIDATED BALANCE SHEET

(Unaudited; Dollars in thousands)

	As of October 31,
	2012
ASSETS
Current Assets:
Cash and cash equivalents	$	28,414
Restricted cash		9,408
Receivables, net		10,542
Inventories, net		5,446
Other current assets		4,311
Income taxes receivable		421
Total Current Assets		58,542
Property and equipment, less accumulated depreciation		1,867
Intangible assets, net		119,641
Other assets		15,531
Total Assets	$	195,581
LIABILITIES
LIABILITIES NOT SUBJECT TO COMPROMISE:
Current  Liabilities:
Accounts payable	$	2,068
Accrued expenses		22,941
Other current liabilities		9,331
Total Current liabilities		34,340
Total Liabilities not subject to compromise		34,340
Total liabilities subject to compromise		672,106
Total Liabilities		706,446
SHAREHOLDERS' DEFICIT
Preferred Stock		0
Class A Common Stock		643
Class B Common Stock		112
Additional paid-in capital		205,802
Accumulated deficit		(660,013	)
Less: Treasury stock		(57,409	)
Total Shareholders' Deficit		(510,865	)
Total Liabilities and Shareholders' Deficit	$	195,581

- 7 -

MOR-4:

STATUS OF POST-PETITION TAXES 1, 2

(Dollars in thousands)

Federal	Beginning Tax			Amount Withheld and/or Accrued		Amount Paid			Ending Tax
Withholding	$	0		$	268	$	(268	)	$	0
FICA-Employee		0			59		(59	)		0
FICA-Employer		0			77		(77	)		0
Total Federal Taxes	$	0		$	404	$	(404	)	$	0
State and Local
Withholding	$	0		$	68	$	(68	)	$	0
Sales Tax		9			1		0			10
Real Property		5			1		0			6
Personal Property		52			0		0			52
Franchise Tax		(17	)		20		(37	)		(34	)
Total State and Local	$	49		$	90	$	(105	)	$	34
Total Taxes	$	49		$	494	$	(509	)	$	34

Notes

1 – The Debtors have not annexed copies of tax returns filed with various taxing authorities during the current reporting period to this MOR, nor have they included the Debtors’ IRS Form 6123 with this MOR.  Copies of such tax returns and IRS Form 6123 will be provided upon reasonable request in writing to counsel for the Debtors.

2 – The Debtors believe they are paying all undisputed taxes and preparing and filing all tax returns when due or obtaining extensions where necessary.

- 8 -

MOR-4 (CON’T):

SUMMARY OF UNPAID POST-PETITION DEBTS 1

(Dollars in thousands)

Description	Amount
0 - 30 days old	$	2,053
31+ days old		15
Total Vendor Accounts Payable Post-petition	$	2,068

Notes

1 – The Debtors believe they are paying all undisputed post-petition obligations according to terms.  

- 9 -

MOR-5:

ACCOUNTS RECEIVABLE RECONCILIATION AND AGING

(Dollars in thousands)

Description	Amount
0 - 30 days old	$	10,892
31 - 60 days old		5
61 - 90 days old		1
90+ days old		913
Total Customer Accounts Receivable	$	11,811
Customer Allowances		(1,269	)
Total Accounts Receivable	$	10,542

- 10 -

MOR-6:

PAYMENTS TO INSIDERS AND PROFESSIONALS

(Dollars in thousands)

INSIDERS

Name	Type of Payment 1	Current Month Amount Paid		Total Paid Since August 4, 2012
Christmas,  Patrick	Salary/Expenses	$	21	$	62
Divis, Gregory	Salary/Expenses		31		89
McHugh, Thomas	Salary/Expenses		24		69
Stancic, Ana	Director Fees		29		29
Hermelin, David	Director Fees		31		31
Sidransky, David MD	Director Fees		30		30
Bentley, Gregory	Director Fees		29		29
Lehrer, Joseph	Director Fees		41		41
Dow, Mark	Director Fees		34		34
Baldini, Robert	Director Fees		30		30
Total		$	300	$	444

Notes

1 – Additional detail concerning payments to the Debtors’ insiders will be provided upon reasonable request in writing to counsel for the Debtors.

PROFESSIONALS 1

Name	Date of Court Order Authorizing Payment	Amount Requested 2		Current Month Amount Paid		Total Paid To Date 3		Total Incurred & Unpaid
Alston & Bird, LLP	September 14, 2012	$	99	$	61	$	61	$	38
Arnall Golden Gregory, LLP	October 10, 2012		-		-		-		-
Duff & Phelps, LLC	October 10, 2012		205		-		-		205
Epiq Bankruptcy Solutions	September 27, 2012		155		65		65		90
Fortgang Consulting	September 14, 2012		-		-		-		-
Houlihan & Lokey Capital, Inc.	September 14, 2012		155		-		472		155
Jefferies & Company, Inc.	October 10, 2012		-		-		-		-
Stroock, Stroock & Lavan, LLP	October 10, 2012		-		-		-		-
Weil, Gotshal & Manges, LLP	September 27, 2012		381		381		381		-
Willkie, Farr & Gallagher, LLP	September 27, 2012		1,455		531		531		924
Total		$	2,450	$	1,039	$	1,510	$	1,412

Notes

1 – Represents professional services exclusive of those rendered by professionals retained by the Debtors pursuant to the September 27, 2012 order of the Bankruptcy Court authorizing the Debtors to employ and retain professionals utilized in the ordinary course of business professional service providers.

2 – Represents amounts requested during the current reporting period.

3 – Represents payments made from the date of the Bankruptcy Court’s order authorizing each firm’s retention.

- 11 -

MOR-6 (CON’T):

POST-PETITION STATUS OF SECURED NOTES, LEASES PAYABLE

AND ADEQUATE PROTECTION PAYMENTS1

(Dollars in thousands)

Name of Creditor	Scheduled Monthly Payment Due		Amount Paid During Month
Building lease payable	$	42	$	42
Total Payments			$	42

Notes

1 – The Debtors’ schedule of lease payments, as set forth in this MOR, only reflects payments made pursuant to the Debtors’ real property lease.  Immaterial leases of personal property are not included in this MOR-6.

- 12 -

MOR-7:

DEBTOR QUESTIONNAIRE

Must be completed each month.  If the answer to any of the questions is "Yes", provide a detailed explanation of each item.  Attach additional sheets if necessary.		Yes	No
1	Have any assets been sold or transferred outside the normal course of business this reporting period?		X
2	Have any funds been disbursed from any account other than a debtor in possession account this reporting period?		X
3	Is the Debtor delinquent in the timely filing of any post-petition tax returns?		X
4	Are workers compensation, general liability or other necessary insurance coverages expired or cancelled, or has the debtor received notice of expiration or cancellation of such policies?		X
5	Is the Debtor delinquent in paying any insurance premium payment?		X
6	Have any payments been made on pre-petition liabilities this reporting period?	X
7	Are any post-petition receivables (accounts, notes or loans) due from related parties?		X
8	Are any post-petition payroll taxes past due?		X
9	Are any post-petition State or Federal income taxes past due?		X
10	Are any post-petition real estate taxes past due?		X
11	Are any other post-petition taxes past due?		X
12	Have any pre-petition taxes been paid during this reporting period?		X
13	Are any amounts owed to post-petition creditors delinquent?		X
14	Are any wages payments past due?		X
15	Have any post-petition loans been received by the Debtor from any party?		X
16	Is the Debtor delinquent in paying any US Trustee fees?		X
17	Is the Debtor delinquent with any court ordered payments to attorneys or other professionals?		X
18	Have the owners or shareholders received any compensation outside of the normal course of business?		X
Explanations
6	Pursuant to various orders entered by the Bankruptcy Court, the Debtors were authorized to pay certain pre-petition employee salary and benefit obligations, as well as certain pre-petition vendor, warehousemen and common carrier obligations.  The Bankruptcy Court also approved the Debtors’ motion to honor certain prepetition obligations to their customers.
13	The Debtors believe that all undisputed post-petition accounts payable have been and are being paid according to agreed-upon terms specific to each vendor and/or service provider.  Any aged amounts represent items subject to valid disputes and certain items which have been paid subsequent to the end of this reporting period.

- 13 -

MAKENA® PERFORMANCE METRICS

Makena® (hydroxyprogesterone caproate injection) is the Debtors’ single-most valuable product.  The information below addresses certain key performance metrics related to Makena®.  The amounts shown are based on estimates and are subject to change.  Gross revenues are preliminary and unaudited, and are not prepared in accordance with GAAP.

Three Months Ended	Gross Revenues ($ in thousands)(1)	Total Prescriptions(2)	Vials Shipped to Customers (3)
9/30/2011	$     1,318	1,255	382
12/31/2011	$     1,670	1,687	484
3/31/2012	$     6,396	2,240	1,854
6/30/2012	$   13,393	2,577	3,882
9/30/2012	$   13,006	3,046	3,770
10/31/2012(4)	$   17,974	3,317	5,210

Notes:

(1) Amounts shown are estimated based on the number of vials shipped and list price/vial.

(2) Represents total prescriptions reported to the Debtors and does not include cancellations.

(3) Represents paid vials shipped to the Debtors' customers, which include specialty pharmacies and distributors.

(4) Data for the months of August, September, and October 2012 is used in the absence of complete data for the three months ending December 31, 2012.

- 14 -